Abstract Submission

Abstracts must be submitted online before 9 March 2026 23:59 CET

Abstracts for the ECM2026 congress must be submitted online via the abstract submission site. Emails and word processing files submitted outside the abstract submission site will not be accepted.

There is no limit to the number of abstracts an author may submit.

It is the author’s responsibility to designate a new presenter for presentation conflicts that arise.

If accepted, the presenter must be a co-author listed on the abstract at the time of submission.

Abstracts must have a complete status by the abstract deadline, or the abstract will not be considered for the ECM2026 program.

It is the responsibility of all authors that studies are performed with respect to national legislation, international legislation, and ethical guidelines with regards to humans and animals.

It is the responsibility of the authors that the author list is correct: all authors must qualify as authors and agree on the contents of the abstract.  

It is the responsibility of the authors that the abstract is written in correct and clear English language. Please ensure that your abstract does not contain spelling, grammatical or scientific errors, as it will be reproduced exactly as submitted. Abstracts will not be proofread. 

Language used should be inclusive and take the wider audience of the ECM2026 into consideration.

The inclusion of trade names/brand names is not allowed in the abstract unless this is peculiar and adds value to their work. The mentioning of agents/molecules must follow the scientific standard for publications.

Categories

Abstract submission must be in one of the following tracks:

• Artificial Intelligence
• Biomarkers
• Cancer and Tumour Microenvironment
• Cardiovascular Diseases
• Cell Senescence and Aging
• Cytokines and Growth Factors
• Degradomics
• Drug Discovery
• ECM Signaling
• Epigenetics
• Fibroaging
• Fibroblasts
• Fibrosis
• Genetics
• Imaging Techniques
• Immunological Diseases
• Inflammation
• Inflammatory Bowel Diseases
• Kidney Diseases
• Liver Diseases
• Lung Diseases
• Matrix Biology
• Models and Experimental Systems
• Multi-Organ Fibrosis
• Musculoskeletal Diseases
• Neurological and Brain Disorders
• Obesity and metabolic Diseases
• Other ECM-related diseases
• Pharmacology
• Precision Medicine
• Proteomic Techniques
• Regenerative Medicine
• Skin Diseases
• Systems Biology
• Vascular Biology
• Women’s Health
• Wound Healing

 Format and length

The length of the abstract should be max. 700 words. This includes main text, excluding funding title, author names and affiliations, as well as funding information and references, if any).

The title should be as brief as possible but long enough to clearly indicate the nature of the study. Please do not include a full stop at the end of the title. As you must enter the title in the abstract system, you should not include it in your abstract document.

Please do not include any author names and institutions in the abstract document. You will enter the name(s) of author(s) and their institution(s) when submitting the abstract online. Please ensure that your email address (submitter and presenting author) is correct. 

The abstract must include the following:

• Introduction & Aim: The abstract should begin with a sentence or two explaining the clinical (or other) importance of the study question. This section should also state the precise aim or study question addressed in the project.
• Methods: Methods should be concise and include the epidemiological design, patient selection (key inclusion/exclusion criteria), description of independent and dependent variables, and most important statistical test.
• Results: This section should describe baseline characteristics of participants followed by primary and secondary outcomes. Report estimates of associations including appropriate measures of variability and uncertainty (e.g., odds ratios with confidence intervals). If authors include tables/figures, please avoid duplicating information that is provided in the table/figures.
• Conclusion: This section should provide only findings of the study directly supported by the results. Authors may state its clinical or future research implications. Please avoid speculation and over-generalization. Give equal emphasis to positive and negative findings of equal scientific merit.
• Tables (characters included count): A maximum of 1 table can be included in the abstract template with the following criteria: Combined maximum number of columns: 12 / rows: 20. The graph should also be uploaded as an image file (max 500 KB) under “Supporting Document”.
• Graphs: A maximum of 1 graph can be included. The graph should also be uploaded as an image file (max 500 KB) under “Supporting Document”.
• Picture: a maximum of 2 pictures (max 500 KB) can be included in the abstract under “Supporting Document”.
• Abstracts can be re-edited and modified until the submission deadline.

Program information

Note: Presenting authors will not be allowed to reschedule their presentation time(s).

• Oral presentation: Oral presentations are 10 minutes in length + questions. Those selected for an oral presentation will receive their presentation details (date/time) in their acceptance letter.
• Lightning-oral presentation: Poster presenters will share their research and highlight novel or recent advancements in a short five-minute presentation. In the end of the session there will be a question-and-answer slot with a session moderator Those accepted for a Rapid-Oral presentation will receive their presentation details (date/time) in their acceptance letter.
• Poster tour presentation: Poster tours gather the most outstanding posters submitted. During the tours, the poster presenters will have the opportunity to present, explain the main results of their work and answer questions during an interactive discussion
• Poster presentation: A poster presentation is an open session where attendees can browse freely and discuss the research directly with the presenter.

All Posters must be displayed for all four days (Sunday, Monday, Tuesday, and Wednesday) in the Poster Area. The presenting author must be available on his/her assigned General Poster Session presentation day(s) to answer questions from attendees. Those accepted for a poster presentation will receive their presentation details (date/time) in their acceptance letter.

The Poster Area will be open all four days. Presenters will have the opportunity to hang their posters on Sunday before the Opening session, so they will be on display during the whole congress.

Review and Acceptance

The Scientific Committee will review and evaluate abstracts.

Authors will be notified of acceptance or rejection of abstracts by 1 April 2026.

For accepted abstracts, the Scientific Committee will determine the presentation type bearing in mind the author’s preference.

Abstracts will be reviewed blinded. The reviewers will judge the abstracts according to the scientific or clinical value, relevance to ECM2026, suitability of methods to aims, conclusions confirmed by objective results, objectivity of statements, description of methods used, ethics, originality of work, standard of English and overall impression.

Abstracts not adhering to these guidelines will be rejected. If you do not agree with any of these rules, you should not submit an abstract.

Abstract publication, revisions, and withdrawals

Submission of an abstract grants ECM2026 the right to publish the abstract on the International Society of Extracellular Matrix Pharmacology (ISECMP) website; https://www.isecmp.org/. All abstracts accepted for the ECM2026 congress will be published on 13 June 2026, unless withdrawn by the withdrawal deadline. The published abstracts will be accessible only to ISECMP members and registered ECM2026 participants and will require login information to view.

Abstracts may be revised online until 9 March 2026. Modifications will not be allowed after the submission deadline.

Abstracts must be withdrawn no later than 31 May 2026, or they will be published on 13 June 2026. To withdraw an abstract, the presenting author must inform the Congress Secretariat via email before the withdrawal deadline.

Abstract presenter expenses/congress registration fee

Abstract presenters will be required to attend ECM2026 in-person to make their presentation. Expenses associated with an abstract presentation (e.g., travel, hotel, congress registration fees, etc.) are the sole responsibility of the presenting author. Presenters must register for the meeting in the appropriate category (Industry, Delegates, Student).

If you register for the meeting and your abstract submission is not accepted for presentation, you may request a full refund of your registration fee (deducting an administration fee of 30 EUR) until 1 May 2026.

Contact

For all inquiries regarding abstracts and speakers, please contact the ECM2026 Conference Secretariat at